FGFR1 rearrangement (myeloid/lymphoid neoplasms)
Gene: FGFR1 · Type: fusion
Indications: Myeloid/lymphoid neoplasms
Linked CIViC Profile: FGFR1 REARRANGEMENT
Evidence Level Distribution
Level B: 21Level C: 6Level D: 15Level E: 1
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Lung Squamous Cell Carcinoma | PD173074 | 5 |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 5 | |
| B | Prognostic | Supports | Poor Outcome | Breast Cancer | 5 | |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Rogaratinib,Palbociclib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Lung Cancer | Ponatinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Lung Squamous Cell Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Cancer | 4 | |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | PD173074 | 4 |
| B | Prognostic | Does Not Support | Poor Outcome | Lung Squamous Cell Carcinoma | 4 | |
| B | Diagnostic | Supports | Positive | Childhood Low-grade Glioma | 4 | |
| D | Predictive | Supports | Resistance | Estrogen-receptor Positive Breast Cancer | CDK4/6 Inhibition,Antiestrogen Therapy | 4 |
| B | Prognostic | Supports | Poor Outcome | Lung Squamous Cell Carcinoma | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Infigratinib | 3 |
| D | Predictive | Supports | Resistance | Breast Cancer | Afimoxifene | 3 |
| D | Predictive | Supports | Sensitivity/Response | Ewing Sarcoma Of Bone | Ponatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Estrogen-receptor Positive Breast Cancer | Ponatinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Squamous Cell Carcinoma | Infigratinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Sarcoma | Fexagratinib,Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 3 |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Lucitanib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Adenosquamous Lung Carcinoma | Pazopanib | 3 |